Businesswire·2026-04-01 02:08Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Apellis Pharmaceuticals, Inc. to Biogen Inc. to assess the adequacy of the price and process involved in the transaction [1]. Summary by Relevant Sections - Proposed Transaction Details - Apellis shareholders are set to receive $41.00 per share in cash along with a nontransferable contingent value right for two additional payments of $2.00 per share, contingent on meeting specific annual global net sales thresholds for SYFOVRE [1]. - Investigation Purpose - The investigation aims to determine whether the proposed consideration undervalues Apellis Pharmaceuticals and whether the process leading to this valuation was adequate [1]. - Contact Information for Investors - Investors who believe the transaction undervalues the company can contact Kahn Swick & Foti, LLC for further discussion regarding their legal rights [2].